Medpace Holdings Securities Fraud Lawsuit, Did MEDP Mislead You as an Investor? Durbin v. Medpace Holdings Inc., No. 26-cv-00346

Medpace Holdings Inc. (NASDAQ: MEDP) is facing a class action lawsuit — Durbin v. Medpace Holdings Inc., No. 26-cv-00346 — filed in U.S. District Court for the Southern District of Ohio, charging Medpace and certain of its top executives with violations of the Securities Exchange Act of 1934. The lawsuit covers investors who purchased or acquired MEDP common stock between April 22, 2025 and February 9, 2026. If you bought Medpace stock during that window and lost money, this case may directly affect you — and the lead plaintiff deadline is June 8, 2026.

Medpace Holdings Securities Fraud Lawsuit — Key Facts

Field	Detail
Lawsuit Filed	2026
Defendant	Medpace Holdings Inc. and certain senior executives
Alleged Harm	Securities fraud — misleading investors about book-to-bill ratio and cancellation rates
Specific Laws Alleged	Sections 10(b) and 20(a) of the Securities Exchange Act of 1934; Rule 10b-5
Who Is Affected	Investors who purchased MEDP common stock April 22, 2025 – February 9, 2026
Court & Case Number	U.S. District Court, Southern District of Ohio — No. 26-cv-00346
Current Court Stage	Active litigation — lead plaintiff selection pending
Lead Plaintiff Deadline	June 8, 2026
Settlement Status	No settlement — active lawsuit
Law Firms Involved	Robbins Geller Rudman & Dowd LLP; Bleichmar Fonti & Auld LLP
Last Updated	May 24, 2026

Who Is Medpace Holdings and Why Are MEDP Investors Suing for Securities Fraud?

Medpace is a clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. It trades on the NASDAQ under the ticker MEDP. Investors rely heavily on Medpace’s forward-looking guidance — particularly its book-to-bill ratio, which measures new business booked against revenue earned — to decide whether to buy, hold, or sell the stock. That guidance is exactly what this lawsuit puts on trial.

What Did Medpace Tell MEDP Investors About Its Business Between April 2025 and February 2026?

The lawsuit alleges that throughout the class period, defendants made false and/or misleading statements and failed to disclose that Medpace consistently oversold its projected book-to-bill ratio for the fourth quarter of 2025; that Medpace knew or recklessly disregarded the impact that cancellations were having on its book-to-bill ratio; and that Medpace frequently claimed a projection of a 1.15 book-to-bill ratio for Q4 2025 was reasonable and achievable.

The lawsuit further alleges that Medpace reassured investors it was not concerned about the lack of diversity in its pre-backlog, and that management stated the company’s upside was broad-based and not isolated to any handful of studies.

In plain terms: investors say Medpace painted a rosy picture of its business pipeline while knowing the reality was far weaker. For investors who relied on those statements when buying MEDP stock, the losses that followed were severe.

This case follows a pattern that securities fraud attorneys call a “corrective disclosure” scenario — similar to what our coverage of the PayPal securities fraud class action lawsuit explains in detail, where a company’s stock drops sharply the moment the truth emerges. If you want to understand how Sections 10(b) and 20(a) of the Securities Exchange Act apply in cases like this, our breakdown of how securities fraud class actions work under the Exchange Act is a useful starting point.

Related article: GKN Aerospace Toxic Chemical Leak Lawsuit, Were You Evacuated from Garden Grove? Filed by The X-Law Group P.C. and Presidio Law Firm LLP on Behalf of Evacuation Zone Residents

The Medpace Disclosures That Sent MEDP Stock Lower — February 9, 2026 and April 23, 2026

February 9, 2026 — Q4 2025 Earnings Release

On February 9, 2026, Medpace released its Q4 2025 financial results, reporting that its book-to-bill ratio declined to 1.04 due to elevated cancellations — well below its own guidance of 1.15. The price of MEDP stock dropped nearly 16%, falling from $530.35 per share on February 9, 2026 to $446.05 per share on February 10, 2026. That is a drop of approximately $84.30 per share in a single trading session. For investors who bought at elevated prices based on the company’s guidance, the hit was immediate and steep.

April 23, 2026 — Continued Deterioration and President’s Resignation

Investigations by securities law firms reveal that Medpace’s cancellations continued to increase and its book-to-bill ratio continued to decline, reaching as low as 0.88 for Q1 2026. The company’s President, Jesse Geiger, also announced his intention to resign. On this news, the price of MEDP stock declined roughly 23% during afternoon trading on April 23, 2026.

The April drop falls outside the current class period end date of February 9, 2026, but it is relevant context for investors assessing the strength of the case and the trajectory of the business.

Are You Part of the Medpace Holdings MEDP Securities Fraud Class Action?

Here is exactly how to know if this lawsuit includes you.

Investors who may be part of this class:

• Anyone who purchased or acquired Medpace Holdings Inc. (NASDAQ: MEDP) common stock between April 22, 2025 and February 9, 2026
• Investors who relied on Medpace’s book-to-bill ratio guidance and suffered financial losses when the stock dropped
• Those who held MEDP shares and were damaged by the February 9, 2026 stock decline following the Q4 2025 earnings release
• Investors who suffered losses due to what the complaint characterizes as false and misleading statements from Medpace’s management during the class period

Investors who are NOT part of this class:

• Those who did not purchase MEDP stock during the April 22, 2025 – February 9, 2026 class period
• Medpace executives, directors, and their immediate family members named in the complaint
• Investors who purchased MEDP shares only before April 22, 2025 or only after February 9, 2026

MEDP Investors Outside Ohio — Are You Still Covered?

Yes. The case is filed in the U.S. District Court for the Southern District of Ohio, but federal securities class actions cover eligible investors nationwide regardless of where they live. If you bought MEDP stock from New York, California, Texas, or any other state during the class period and suffered a loss, you are still a potential class member. The court’s jurisdiction covers all investors in U.S. markets.

If you are unsure whether you qualify for the Medpace MEDP securities fraud lawsuit, a free consultation with a securities fraud attorney can help you assess your losses before the June 8, 2026 deadline.

What Are Medpace MEDP Investors Asking the Court to Award in the 2026 Securities Fraud Lawsuit?

The complaint seeks compensatory damages, disgorgement of profits, and attorneys’ fees for investors who suffered losses during the class period. No specific settlement dollar amount has been proposed — this case is in active litigation.

What Could Medpace MEDP Investors Receive If the 2026 Securities Fraud Case Settles?

No money is available yet, and no claim form exists. In securities fraud class actions of this type, potential recoveries depend on the number of investors who come forward, the size of their documented losses, the strength of the evidence, and what the parties negotiate. It is impossible to predict a per-share recovery at this stage. A securities fraud attorney can give you a more accurate sense of your potential recovery based on your specific transaction history and loss amount.

What Should Medpace MEDP Investors Do Right Now?

Most class members are automatically included once a class is certified — you do not need to take action today just to preserve your rights as a general class member. But the lead plaintiff deadline is June 8, 2026, and that matters if you had substantial losses.

1. Pull your brokerage statements showing all MEDP purchases between April 22, 2025 and February 9, 2026, including trade confirmations and account records
2. Calculate your losses by comparing what you paid for MEDP shares against the prices after the February 9, 2026 disclosure — the difference is your alleged loss
3. Determine if you want to apply as lead plaintiff — if you had significant losses, you have until June 8, 2026 to file a motion with the court. The lead plaintiff directs the litigation and typically receives a larger share of any recovery
4. Contact Robbins Geller Rudman & Dowd LLP at 800-851-7783 or [email protected] if you want to discuss lead plaintiff status — there is no cost to contact them
5. Monitor the docket at the U.S. District Court for the Southern District of Ohio under case No. 26-cv-00346 via PACER for all case updates
6. Do not sell any documentation — keep all account statements, trade confirmations, and records of your MEDP transactions until this case is resolved

Medpace Holdings MEDP Securities Fraud Lawsuit Timeline

Milestone	Date
Class period begins	April 22, 2025
Medpace provides book-to-bill guidance of 1.15 for Q4 2025	During class period
Class period ends	February 9, 2026
Q4 2025 earnings released — book-to-bill reported at 1.04	February 9, 2026
MEDP stock drops ~16%, from $530.35 to $446.05	February 9–10, 2026
Lawsuit filed — Durbin v. Medpace Holdings Inc.	2026
Q1 2026 book-to-bill falls to 0.88; President Jesse Geiger announces resignation	April 23, 2026
MEDP stock drops ~23% on April 23 news	April 23, 2026
Lead plaintiff deadline	June 8, 2026
Class certification hearing	TBD — not yet scheduled
Expected resolution	TBD — early-stage litigation

Medpace Holdings Securities Fraud Lawsuit — Frequently Asked Questions, No. 26-cv-00346

Is there a class action lawsuit against Medpace Holdings for securities fraud right now?

 Yes. The lawsuit, captioned Durbin v. Medpace Holdings Inc., No. 26-cv-00346, is filed in the U.S. District Court for the Southern District of Ohio, and charges Medpace and certain of its top executives with violations of the Securities Exchange Act of 1934. The case is active. No settlement has been reached.

Do I need to do anything right now to be included in the Medpace MEDP securities fraud class action?

 Not for general membership — most investors who bought MEDP stock between April 22, 2025 and February 9, 2026 and suffered losses will be included automatically if the class is certified. However, if you want to serve as lead plaintiff, you must file a motion with the court by June 8, 2026.

When will the Medpace securities fraud case settle?

 There is no timeline available yet. Securities fraud class actions of this type typically take two to four years from filing to final resolution. The court has not scheduled a class certification hearing as of the date of this article.

Can I file my own lawsuit against Medpace for securities fraud instead of joining the class? 

Yes, individual lawsuits are possible but require you to hire your own attorney and prove your damages separately. Most investors find a class action more practical and cost-effective. A securities fraud attorney can help you compare both options based on the size of your losses.

How will I find out if the Medpace lawsuit settles?

 Monitor the court docket under case No. 26-cv-00346 at the U.S. District Court for the Southern District of Ohio via PACER. AllAboutLawyer.com will update this article as material developments occur.

What does “lead plaintiff” mean, and why does the June 8, 2026 deadline matter? 

A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class. A lead plaintiff acts on behalf of all other class members in directing the class action lawsuit and can select a law firm of its choice to litigate the case. If you had substantial losses in MEDP during the class period, you have until June 8, 2026 to file your motion. After that date, the court selects from whoever applied.

What specific laws does Medpace allegedly violate in this securities fraud lawsuit?

 The lawsuit charges Medpace and certain of its executives with violations of the Securities Exchange Act of 1934. Specifically, this means Sections 10(b) and 20(a) and SEC Rule 10b-5 — the core federal statutes that prohibit companies from making materially false statements or omissions that mislead investors in connection with the purchase or sale of securities.

How much could Medpace MEDP investors recover from a future securities fraud settlement? 

No number is possible to predict at this stage. Recoveries in securities class actions depend on the total investor losses documented, the number of class members, and negotiated settlement terms. MEDP stock fell nearly 16% on February 9–10, 2026 alone, which gives attorneys a baseline for calculating class-wide damages. Speaking with a securities fraud attorney is the most reliable way to estimate your individual recovery potential.

Sources Used in This Medpace Holdings Securities Fraud Article

• Robbins Geller Rudman & Dowd LLP — Official case page, Durbin v. Medpace Holdings Inc., No. 26-cv-00346: https://www.globenewswire.com/news-release/2026/05/21/3299691/0/en/investor-alert-medpace-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-rgrd-law-announces-medp.html

Prepared by the AllAboutLawyer.com Editorial Team and reviewed for factual accuracy against the Robbins Geller official case page, SEC EDGAR filings, and PR Newswire announcements on May 24, 2026. Last Updated: May 24, 2026.

Disclaimer: This article is for informational purposes only and does not constitute legal advice. For advice about your specific situation, consult a qualified attorney.